

096P ROSIGLITAZONE-INDUCED VASORELAXATION IN THE RAT AORTA

S.E. Cunnane, Y.Y. Chan & M.D. Randall, School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH.

Thiazolidinediones are a group of peroxisome proliferator-activated receptor gamma (PPAR- γ ,) agonists which were the first class of insulin sensitizers to be introduced for the management of type II diabetes mellitus. In addition to their beneficial effects on glucose control, Nolan *et al.* (1994) reported that treatment of type II diabetic patients with troglitazone resulted in a decrease in blood pressure. It has been proposed that troglitazone and rosiglitazone exert direct vascular effects, via inhibition calcium channels (Song *et al.*, 1997). In the present study, we have investigated the involvement of nitric oxide (NO), and Ca²⁺ channels in vasorelaxation to rosiglitazone in rat isolated thoracic aorta.

Male Wistar rats (225–250g) were stunned by a blow to the back of the head, and then killed by exsanguination. Thoracic aortae were removed and placed in organ baths containing oxygenated Krebs-Henseleit solution, and were mounted as 2-3mm rings for isometric recording (Tep-areenan *et al.*, 2003). The rings were then set to a resting tension of 10mN and allowed to equilibrate for 1h. Following equilibration, the rings were contracted with methoxamine (100 μ M). The role of NO was investigated by carrying out some experiments in the presence of 300 μ M N^G-nitro-L-arginine methyl ester (L-NAME). In some cases the role of the endothelium was investigated by rubbing the inner surface with a wooden stick to remove the endothelium. In some preparations, the effects of rosiglitazone were investigated against calcium influx; briefly aortae were bathed in calcium-free buffer and then contractile responses to CaCl₂ were determined in the presence of 100mM KCl (Tep-areenan *et al.*, 2003).

The acute presence of rosiglitazone (100nM-30 μ M) did not induce significant relaxation in the rat aorta (n=6). However, prolonged exposure to rosiglitazone (30 μ M) elicited significant vasorelaxation (20.6 \pm 6.2%, mean \pm s.e.mean) 50 minutes after being added and then caused time-dependent relaxations of methoxamine-induced tone (n=11) such that after 120 minutes, the relaxation to rosiglitazone was 36.8 \pm 8.0%. Removal of the endothelium abolished vasorelaxation to rosiglitazone (30 μ M, n=5). Rosiglitazone (30 μ M)-induced vasorelaxations in rat aorta were reduced significantly (P<0.05, Student's t-test) in the presence 300 μ M L-NAME (Control: 26.0 \pm 7.2 %, n=6; L-NAME: 4.4 \pm 2.7 %, n=5). In Ca²⁺-free buffer the addition of CaCl₂ (10 μ M–30mM) caused concentration-dependent contractions in the rat aorta depolarised by 100mM KCl. Pre-treatment with 30 μ M rosiglitazone did not affect maximal contractions induced by CaCl₂ (Vehicle: 5.49 \pm 0.50mN; rosiglitazone: 4.80 \pm 0.40mN; n= 4).

In conclusion, the present findings demonstrate that rosiglitazone causes vasorelaxation on prolonged exposure, and this is largely mediated via endothelium-derived NO.

Nolan *et al.* (1994). *New Engl. J. Med.*, **331**, 1188-1193.

Song *et al.* (1997). *Diabetes*, **46**, 659-664.

Tep-areenan *et al.* (2003). *Eur. J. Pharmacol.* **465**, 125-132.